Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05995860
Other study ID # CTO-IUSCCC-0827
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date June 14, 2023
Est. completion date December 2024

Study information

Verified date November 2023
Source Indiana University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to help test an idea designed to foster more supportive talk between providers (doctors or nurse practitioners), patients, and caregivers during an outpatient oncology appointment. A caregiver is the person the patient identifies is primarily involved in their healthcare. This study is collecting your reaction to this idea in order to understand needed changes before we introduce the idea to a larger group of patients.


Description:

This pilot study focuses on an intervention (freelisting) designed to elicit supportive oncology communication intentions among the patient-caregiver-provider triad prior to an outpatient oncology encounter. The goal is to shape communication behaviors during the encounter to improve outcomes of the encounter.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 60
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - patients will: 1. be adult women with an advanced, incurable gynecologic cancer (Stage III/IV disease at diagnosis combined with evidence of refractory/progressive disease after first-line treatment or recurrent disease), 2. be at a transition point in the illness (provider confirmed non-response to treatment, progressive disease, or a symptomatic hospitalization within the last month), 3. not be receiving specialty palliative care or hospice, 4. read/speak English, and 5. be able to provide written informed consent. - caregivers will: 1. identify as the individual who is primarily involved in the patient's care, 2. be able to attend the oncology encounter, 3. read/speak English, and 4. be able to provide written informed consent. - providers will: 1. specialize in gynecologic oncology, and 2. provide outpatient care at IUSCCC gynecologic oncology clinic. Exclusion Criteria: patients and/or caregivers will be excluded if either one or both demonstrate: 1. cognitive impairment, or 2. speech/hearing difficulties precluding participation.

Study Design


Intervention

Behavioral:
Intervention group triads
The intervention consists of a rapid (less than 10-minute) communication intention elicitation exercise (via Freelisting), which is conducted independently with the patient, caregiver, and provider immediately prior to the outpatient oncology encounter. Patients, caregivers, and providers will not be instructed to endorse the Freelist responses that were generated by the intervention prior to the outpatient encounter-leaving the decision to discuss elicited communication intentions during the encounter up to individuals as the conversation naturally occurs. As with the control group, post-encounter survey data will also be collected independently from the patient, caregiver, and the provider, followed by a post-encounter qualitative interview conducted jointly with the patient and caregiver.

Locations

Country Name City State
United States Indiana University Melvin and Bren Simon Comprehensive Cancer Center Indianapolis Indiana

Sponsors (2)

Lead Sponsor Collaborator
Indiana University American Cancer Society, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Evaluate overall recruitment rates. PRECursOr will meet or exceed feasibility (overall recruitment, recruitment rate, measure completion, encounter duration). Once all surveys in the sample size are completed, 9 months anticipated
Primary Evaluate overall participant satisfaction surveys. PRECursOr will meet or exceed acceptability (satisfaction, acceptability of approach) benchmarks per patient and caregiver questionnaire. Once all surveys in the sample size are completed, 9 months anticipated
Primary Explore group differences in communication behaviors during the audio-recorded encounters. The intervention group will demonstrate increased communication behaviors during the encounter (i.e., breadth of supportive oncology domains discussed) and a trend toward greater benefits in the immediate (e.g., quality of communication) and proximal (e.g., shared understanding of treatment goals, distress, anxiety) outcomes of communication. Once all encounters in the sample size are completed and transcribed, 9 months anticipated
Primary Explore group differences in exit interview outcomes following the encounters. The intervention group will demonstrate increased communication behaviors and a trend toward greater benefits in the immediate (e.g., quality of communication) and proximal (e.g., shared understanding of treatment goals, distress, anxiety) outcomes of communication. Once all encounters in the sample size are completed and transcribed and survey/interview completion, 9 months anticipated
Primary Identify intervention approaches in exit interview that contributed to positive and/or negative outcomes Identify intervention approaches that contributed to positive and/or negative outcomes to inform intervention refinement using qualitative research methods. Once all surveys in the sample size are completed, 9 months anticipated
See also
  Status Clinical Trial Phase
Completed NCT01010126 - Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Phase 2
Terminated NCT00899093 - YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy
Completed NCT00301756 - Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors Phase 2
Completed NCT00262847 - Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Phase 3
Recruiting NCT01000259 - Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer N/A
Completed NCT00066456 - Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer Phase 1
Withdrawn NCT00551265 - Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy N/A
Completed NCT03188432 - Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Phase 2
Completed NCT03297489 - Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian Cancer Early Phase 1
Withdrawn NCT00053235 - Research Study in Patients With Advanced Ovarian Epithelial Cancer N/A
Completed NCT00194714 - Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab Phase 1/Phase 2
Terminated NCT02441140 - Detection of Tumor Associated Cell-free DNA in Peritoneal Fluid Obtained by Culdocentesis N/A
Completed NCT01131234 - Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors Phase 1
Recruiting NCT05659381 - Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer Phase 3
Terminated NCT00003532 - Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Ovarian Cancer Phase 2
Completed NCT01551745 - Salvage Ovarian FANG™ Vaccine + Bevacizumab Phase 2
Completed NCT01522820 - Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors Phase 1
Not yet recruiting NCT06315270 - To Explore the Feasibility of Dynamic Changes of TCR Diversity in Peripheral Blood in Monitoring Recurrence and Evaluating Prognosis of Epithelial Ovarian Cancer
Withdrawn NCT02872519 - PET Imaging of Ovarian Carcinoma With 18F-FSPG Early Phase 1
Withdrawn NCT02567396 - Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Phase 1